<?xml version="1.0" encoding="UTF-8"?>
<ref id="CIT0021">
 <label>21.</label>
 <mixed-citation publication-type="journal">
  <person-group person-group-type="author">
   <name name-style="western">
    <surname>Barrett</surname>
    <given-names>PN</given-names>
   </name>, 
   <name name-style="western">
    <surname>Terpening</surname>
    <given-names>SJ</given-names>
   </name>, 
   <name name-style="western">
    <surname>Snow</surname>
    <given-names>D</given-names>
   </name>, 
   <name name-style="western">
    <surname>Cobb</surname>
    <given-names>RR</given-names>
   </name>, 
   <name name-style="western">
    <surname>Kistner</surname>
    <given-names>O</given-names>
   </name>
  </person-group>
  <article-title>Vero cell technology for rapid development of inactivated whole virus vaccines for emerging viral diseases</article-title>. 
  <source>Expert Rev Vaccines</source>. 
  <year>2017</year>;
  <volume>16</volume>:
  <fpage>883</fpage>â€“
  <lpage>94</lpage>. doi:
  <pub-id pub-id-type="doi">10.1080/14760584.2017.1357471</pub-id>.
  <pub-id pub-id-type="pmid">28724343</pub-id>
 </mixed-citation>
</ref>
